Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pharmacokinetics (PK) study of ZL-2306 in Chinese patients with platinum-sensitive ovarian cancer

Next Previous
Search
Trial Profile

A pharmacokinetics (PK) study of ZL-2306 in Chinese patients with platinum-sensitive ovarian cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niraparib (Primary)
  • Indications Ovarian cancer
  • Focus Pharmacokinetics

    • Most Recent Events

    • 16 Mar 2020 According to Zai Lab maedia release, this study was published in August 2019 in The Oncologist.
    • 30 May 2018 New trial record
    • 21 May 2018 According to Zai Lab maedia release, company has successfully completed enrollment three months ahead of schedule and expect to finalize the data from this study by mid-2018, also earlier than planned.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top